Previous Article | Next Article 
Infect Immun, June 1998, p. 2420-2425, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Biophysical Characterization of the Stability of the
150-Kilodalton Botulinum Toxin, the Nontoxic Component, and the
900-Kilodalton Botulinum Toxin Complex Species
Flora
Chen,1
Geoffrey M.
Kuziemko,2,3 and
Raymond C.
Stevens2,3,*
Graduate Group in
Biophysics1 and
Department of
Chemistry,2 University of California, and
Material Sciences Division, Lawrence Berkeley National
Laboratory,3 Berkeley, California 94720
Received 2 February 1998/Returned for modification 16 February
1998/Accepted 4 March 1998
 |
ABSTRACT |
Botulinum neurotoxin serotype A is initially released from the
bacterium Clostridium botulinum as a stable 900-kDa
complex. The serotype A 900-kDa complex is one of the forms of the
toxin being used as a therapeutic agent for the treatment
of various neuromuscular disorders. Previous experiments have
demonstrated that the 900-kDa complex form of the toxin protects the
toxin from the harsh conditions of the gastrointestinal tract. To
provide molecular level details of the stability and equilibrium of the 900-kDa complex, the nontoxic component, and the toxic
(botulinum neurotoxin) component, the three species have been
investigated with a series of biophysical techniques at the molecular
level (dynamic light scattering, proteolysis, circular dichroism, pH incubations, and agglutination assays). These experiments were conducted under harsh conditions which mimic those found along the gastrointestinal tract. Separately, exposure to denaturing and
proteolytic conditions degrades both the botulinum neurotoxin and the
nontoxic component. In the 900-kDa complex, the botulinum neurotoxin is
protected during exposure to the gastrointestinal environment and the
nontoxic component is slightly modified. Surprisingly, the toxin
protects the ability of the nontoxic component to agglutinate erythrocytes. Contrary to previous reports, the purified 900-kDa complex did not have agglutination ability until after exposure to the
proteolytic conditions. These experiments provide new evidence and
detail for the theory that the nontoxic component and the toxic
component protect one another during exposure to harsh conditions, and
a molecular model is presented for the passage of the toxin through the
gastrointestinal tract.
 |
INTRODUCTION |
Botulinum neurotoxin is secreted by
the anaerobic bacterium Clostridium botulinum as one of
seven serotypes, classified A through G (35). The different
serotypes proteolytically cleave specific proteins involved in synaptic
vesicle docking that are necessary for cellular communication at the
neuromuscular junction (12). Serotype A can be purified as a
900-kDa complex (BoNTA-HA) consisting of a toxic component (BoNTA
[botulinum neurotoxin serotype A]) and a nontoxic component (HA
[hemagglutinin]) (5-7). Studies involving relative oral
toxicities (26, 33), intestinal absorption (34),
and comparison to tetanus toxin (31) have indicated that the
complex, not the botulinum toxin alone, is responsible for the
extremely low amount of botulinum neurotoxin required in botulism
poisoning.
The most common mechanism of botulism poisoning is through oral
ingestion of the complex, which is found in food contaminated with
C. botulinum. Ingested spores of the bacteria may also
colonize and produce toxin in the intestinal tracts of infants,
resulting in infant botulism (36). Previous experiments have
demonstrated that the 900-kDa complex protects the toxin during its
exposure to harsh conditions. Ohishi and coworkers (26) have
demonstrated that the 900-kDa complex has a 360-fold-higher oral
toxicity in rats than the 150-kDa botulinum neurotoxin component alone.
Most proteins are broken down into peptides and amino acids in the stomach and small intestine during the process of digestion
(2). However, the 900-kDa complex enters the stomach and
withstands the acidic (pH 2) gastric juice containing the
protease pepsin. The complex then enters the small intestine, where it
encounters several more proteases (trypsin, chymotrypsin, and
carboxypeptidase) that function at pH 7 to 8. Despite these harsh
denaturing and proteolytic conditions, active botulinum neurotoxin
(13, 22) and nontoxic component (34) can be
detected in the lymph and circulatory systems.
The botulinum neurotoxin is comprised of a C-terminal 100-kDa heavy
chain and an N-terminal 50-kDa light chain linked by a disulfide bond.
From C terminus to N terminus, the protein can be further divided
into three 50-kDa functional domains (3, 4, 18)
binding,
translocation, and catalytic
which allow the protein to bind a cell
surface receptor, pass across the membrane (29), and cleave
a protein involved in synaptic vesicle docking (12),
respectively. The nontoxic component is composed of several protein
subunits and can be separated into nontoxic agglutinating proteins
(14, 17, 32) and nontoxic nonagglutinating proteins (11, 14). Several subcomponents of the nontoxic component have been characterized. One of the nontoxic nonagglutinating proteins
is a single peptide of 120 kDa and has been sequenced (11).
The molecular weights of the subcomponents of the nontoxic agglutinating portion have also been determined (14, 32). However, the physiological role and molecular organization of the
nontoxic component are not well understood. In addition, many of the
studies of toxin exposure to harsh conditions have been conducted
with crude cell supernatant. To understand the stability and
equilibrium of the botulinum neurotoxin complex and its separated components at the molecular level, we conducted a series of biophysical experiments using pure preparations of botulinum neurotoxin, botulinum neurotoxin complex, and the nontoxic agglutinating portion.
 |
MATERIALS AND METHODS |
Purification of proteins.
For all experiments, proteins were
obtained as ammonium sulfate precipitates and were purified by
ion-exchange chromatography as previously described (5).
Light scattering.
The hydrodynamic radius, estimated
molecular weight, and polydispersity of protein samples were determined
by using a Dynapro-801 dynamic light scattering instrument
(Protein Solutions, Charlottesville, Va.). Samples of botulinum
neurotoxin (0.18 mg/ml), nontoxic component (0.20 mg/ml), and 900-kDa
complex (0.22 mg/ml) were incubated for 30 min at 4°C over a range of
pHs in 10 mM buffers containing 100 mM sodium chloride. Buffers
were citric acid (pH 1 to 5) (citric acid has three
pKas at 25°C; pK1 = 3.128, pK2 = 4.761, and pK3 = 6.396),
bis-Tris [bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane; pH 6], HEPES (pH 7 to 8), and CHES
[2-(N-cyclohexylamino)ethanesulfonic acid] (pH
9 to 10). Individual samples were recorded for at least 5 min,
during which 12 to 13 data points were taken and then analyzed by using
a monomodal fitting program. The polydispersity served as the deviation
of the size distribution based on the mean hydrodynamic radius of each
sample. Experiments were performed in triplicate.
Test for pH effects.
Protein samples were incubated at the
appropriate pH for 48 h at 4°C. Protein samples were subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
on a 12% polyacrylamide gel, and the bands were visualized with silver
stain (10).
Proteolysis.
Proteins were incubated at various pHs and with
several protease mixtures. Each protein sample contained 2 ml of
protein (0.42 mg/ml) in dialysis tubing with a 50-kDa pore size.
Dialysis tubing containing the protein sample was placed into the
appropriate protease mixture. The mixture was incubated with gentle
stirring for 2 h at 37°C. Pepsin incubations were performed with
0.4 mg of pepsin per ml in 10 mM hydrochloric acid (pH 2). Intestinal cocktail consisted of trypsin (0.02 mg/ml), chymotrypsin (0.03 mg/ml),
and carboxypeptidase A (0.02 mg/ml) in 50 mM sodium bicarbonate-100 mM
sodium chloride buffer (pH 8). Protease concentrations used were chosen
based on reported values (15, 16), though the physiological
protease concentration depends on the feeding state of the organism.
After incubation, proteases were quenched with 0.5 ml of pepstatin (1 mg/ml) or phenylmethylsulfonyl fluoride (17.4 mg/ml) and 1 ml of 0.5 M
EDTA. Proteins were also exposed to incubation of pepsin followed by
intestinal cocktail or incubation at pH 2 followed by intestinal
cocktail. Gels were 12% polyacrylamide, and protein bands were
visualized with silver stain (10).
Circular dichroism.
Circular dichroic spectra were gathered
on a model J-600 spectropolarimeter (Jasco, Easton, Md.) at 37 and
25°C. The bandwidth used was 1 nm, and the step resolution was 2 nm.
Four scans of each sample were made, using a time constant of 1 s
and a scan rate of 50 nm/min. The cell volume was approximately 1 ml,
with a path length of 0.1 cm. The cell was jacketed for temperature adjustment and controlled by using a water bath. Proteins at a concentration of 0.025 mg/ml were dialyzed extensively in their buffers
before being examined on the spectropolarimeter. The pH 6 and pH 8 buffers were 100 mM sodium phosphate containing 100 mM sodium chloride.
The pH 2 buffer was 60 mM hydrochloric acid-potassium chloride buffer
containing 100 mM NaCl. No appreciable difference in signal was
observed at 37 and 25°C; thus, only 37°C data are shown.
ELISA.
Botulinum neurotoxin (0.01 mg/ml) was incubated in
pepsin (0.4 mg/ml) and intestinal cocktail (see above) for 2 h at
37°C. The concentration of substrate protein used was the minimum
amount of protein necessary to give strong enzyme-linked immunosorbent assay (ELISA) signal. Using single-chain variable fragments of mouse or
of human monoclonal antibodies, ELISAs were performed on proteolyzed
samples as described by Chen et al. (5).
Surface plasmon resonance.
Binding of botulinum neurotoxin
and 900-kDa complex to lipid was monitored by using surface plasmon
resonance on a BIAcore 2000 (Biosensor, Piscataway, N.J.). Botulinum
neurotoxin (84 to 1,300 nM) or 900-kDa complex (52 to 832.5 nM) was
injected over a lipid monolayer containing
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). The
lipid monolayer was formed by incubating a solution of POPC liposomes
(2 mg/ml) on a BIAcore sensorchip (type HPA) overnight in a moist
environment. Liposomes were made by sonicating a solution of POPC in a
buffer of 10 mM Tris (pH 7.0) containing 100 mM sodium chloride and 2 mM sodium azide. The experiments were performed at a flow rate of 40 ml/min for 20 min in running buffer of 10 mM Tris (pH 7.0) containing
100 mM sodium chloride and 2 mM sodium azide.
Sugar binding.
Agglutination assays were performed as
previously described (20). Erythrocytes (RBC) from rabbits
were washed twice with saline (68 mM sodium citrate, 146 mM sodium
chloride [pH 7.4]), spun at 4,000 × g, and diluted
to 0.5% for each assay. Protein solution (0.5 ml) at twice the desired
concentration was added to a disposable semimicrocuvette. Then 0.5 ml
of the 0.5% RBC was added to the protein, resulting in the desired
protein concentration and a 0.25% RBC solution. The mixture was
incubated at 37°C for 2 h, and the transmittance was measured at
405 nm in a Shimadzu UV-160 spectrophotometer. The saline control
contained 0.25% RBC incubated in saline for 2 h at 37°C. Each
sample was performed in triplicate. The 900-kDa complex and nontoxic
component were also proteolyzed and then used in an agglutination
assay. The saline control was subtracted from the values for the other
samples. The agglutination ability of the unproteolyzed HA was scaled
to a value of 100. The agglutination abilities of the other samples represent their percent transmittances relative to the percent transmittance by unproteolyzed HA. Previous reports (20)
show that the 900-kDa BoNTA-HA complex is capable of agglutination at lower temperatures. When we performed the agglutination assay at a
lower temperature (12°C), we observed that the complex showed an
increased ability to agglutinate RBC, consistent with the literature but not physiologically relevant.
 |
RESULTS AND DISCUSSION |
Light scattering.
Dynamic light scattering was used to
determine the aggregation state and stability of the three species
under a variety of conditions simulating the environments in the
gastrointestinal tract. This technique measures the diffusion
coefficient of particles in solution, allowing a radius and estimated
molecular weight to be calculated. A molecular weight calculated to be
higher than expected indicates a deviation from a spherical shape. This
deviation may be due to nonspherical species, denatured protein, or the presence of large aggregates of many proteins. The distribution of
particle sizes is indicated by the polydispersity value. A polydispersity of zero signifies that there is only one particle size
in solution. A large polydispersity value indicates the presence of
different-size particles in solution. Examination of the radii of the
three molecular species between pH 1 and 10 yielded a number of
intriguing results. From the hydrodynamic radii the corresponding molecular weights were calculated, assuming an approximate, spherical shape for the protein.
Between pH 10 and 4, the estimated molecular mass of BoNTA was
determined to be approximately 150 kDa (Fig. 1A and
D), corresponding to the expected
molecular mass of a single BoNTA molecule (6). Upon
incubation at pH 3 to 1, botulinum neurotoxin showed steadily higher
values for molecular mass, from 150 to over 1,000 kDa, during the first
10 min in the corresponding buffer. The polydispersity also increased
dramatically as the pH changed from 3 to 1. These higher values for
polydispersity correlated with aggregation and acid-catalyzed
degradation of the neurotoxin molecule. This result is consistent with
botulinum neurotoxin retaining little toxicity at pH 3 to 1 (33). Examination of the nontoxic component at various pHs
revealed behavior similar to that of the botulinum neurotoxin (Fig. 1B
and D). The nontoxic component did not aggregate or disassemble between
pH 10 and 5 and had an apparent estimated molecular mass of
approximately 962 kDa. The molecular mass calculated by light
scattering differs from that calculated by subtracting the molecular
mass of the BoNTA from the molecular mass of the BoNTA-HA
complex because the nontoxic component most likely is not spherical.
Since the light scattering device calculates a molecular mass by a
formula that assumes the protein is a sphere, deviations in
sphericality will result in deviations in molecular mass. The nontoxic
component aggregated, disassembled, or denatured when the pH dropped
from pH 5 to 4, corresponding to a sharp increase in the polydispersity
between pH 5 (0%) and 4 (polydispersity/radius = 18.1%). Below
pH 4, the nontoxic component increased in size to over 2,000 kDa. In
contrast to the botulinum neurotoxin and the nontoxic component, the
entire BoNTA-HA complex was most stable and monodisperse between pH
1 and 4 (Fig. 1C and D), correlating with the observation that the
BoNTA-HA complex retains over 60% of its toxicity at low pH
(33). Between pH 5 and 7, the complex reached its maximum
size. Near neutral pH, the complex reached its maximum polydispersity.
A similar high polydispersity was observed upon ultracentrifugation at
pH 7.5 (37). Above pH 8, the complex appeared as a more
polydisperse species, suggesting the presence of more than one species
in solution probably due to disassociation of the complex into the
toxic and nontoxic components. This idea of dissociation at basic pH is
supported by the procedure for purifying botulinum neurotoxin from the
complex, since high pH is necessary for separation of toxic and
nontoxic components (6, 7).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
Dynamic light scattering results, expressed as pH versus
apparent radius and molecular weight of botulinum neurotoxin (A),
nontoxic component (B), and 900-kDa complex (C) at various pHs. (D)
Estimated molecular weights (MW) of botulinum neurotoxin (triangles),
nontoxic component (squares), and 900-kDa complex (circles). The bar
around each data point represents the average polydispersity value for
three separate experiments. The polydispersity is the deviation of size
distributions based on the mean radius measurement. Specimens
containing aggregates or unfolded proteins have large polydispersity
values.
|
|
pH effects.
The effect of pH on the neurotoxin's structural
stability was examined by SDS-PAGE. A polyacrylamide gel of botulinum
neurotoxin incubated at pH 2, 6, and 8 for 48 h indicated that the
neurotoxin is susceptible to breakdown at pH 2 and 8 (Fig.
2). Table 1
shows that nonincubated neurotoxin runs as a 100-kDa heavy chain and a
50-kDa light chain. After 48 h of incubation at pH 6, we observed primarily the 100-kDa heavy chain and 50-kDa light chain of botulinum neurotoxin. A band at 150 kDa corresponded to a small quantity of
unnicked neurotoxin. Although the 100- and 50-kDa bands predominated at
pH 2 and 8, we observed a ladder of many lower-molecular-weight fragments. This fragmentation could be a result of acid-catalyzed hydrolysis, base-catalyzed hydrolysis, or proteolysis.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 2.
SDS-PAGE of botulinum neurotoxin incubated at pH 2, 6, and 8. Arrows identify the heavy chain (100 kDa) and light chain (50 kDa) of botulinum neurotoxin. The band appearing at approximately 150 kDa is unnicked neurotoxin.
|
|
Proteolysis.
Besides pH extremes, the other stresses
that the 900-kDa complex must endure come from proteases. The
effects of proteases on botulinum neurotoxin, nontoxic component,
and 900-kDa complex were observed by performing protease incubations
and assaying the results by gel electrophoresis (Table 1). Incubations
consisted of pepsin at pH 2, intestinal cocktail (trypsin,
chymotrypsin, carboxypeptidase) at pH 8, and pepsin at pH 2 followed by
intestinal cocktail at pH 8. When incubated individually, both the
neurotoxin and the nontoxic component were susceptible to all of the
protease incubations (Table 1). In contrast, the 900-kDa complex
demonstrated an amazing resistance to proteolysis. After incubation in
pepsin at pH 2, the 900-kDa complex lost none of its bands. When the 900-kDa complex was incubated in intestinal cocktail, the 100- and
50-kDa bands of botulinum neurotoxin were proteolyzed along with
the 120- and 106-kDa bands of the nontoxic component.
However, incubating the 900-kDa complex in pepsin at pH 2 before
exposing the complex to intestinal cocktail inhibited the proteolysis
of the bands corresponding to botulinum neurotoxin. The bands which have been previously shown to be responsible for agglutination (14, 19, 21, 35, and 52 kDa) (14, 32) remained intact according to
our gel whereas the band previously shown to be
nontoxic-nonagglutinating (11) was destroyed.
Thus, under conditions that simulate the path of the 900-kDa complex
through the gastrointestinal tract, the nontoxic component protected
botulinum neurotoxin from proteolysis. This protection of the
neurotoxin could be due to exposure to pepsin or to acidic pH. To
determine if the protection of botulinum neurotoxin was a result of low
pH, we performed an incubation without pepsin at pH 2, followed by an
intestinal cocktail incubation. With these conditions, we observed that
low pH was sufficient for protecting the complexed botulinum neurotoxin
from proteolysis (data not shown). This protection of the botulinum
neurotoxin in the 900-kDa complex was also seen upon incubations in rat
gastric juice (33).
Circular dichroism.
Circular dichroic spectra of the botulinum
neurotoxin, the nontoxic component, and the complex were taken at 37 and 25°C to determine the effects of pH on the structure and
stability of the proteins. Temperature appeared not to have an effect
on the spectra. At pH 2, 6, and 8, the 900-kDa complex shows little
change in secondary structure (Fig. 3A).
Thus, the increased protease resistance of the 900-kDa complex, upon
exposure to pH 2, did not result from a visible conformational change
in the secondary structure. When the nontoxic component was studied at
pH 6 and 8, it likewise showed minor change in secondary structure
(Fig. 3B). Upon exposure to pH 2, the nontoxic component showed a
slight decrease in helicity. This loss of secondary structure is not large enough to indicate that the nontoxic component significantly unfolds. Since individual nontoxic components do not unfold, an increase in hydrodynamic radius, which corresponds to an increase in
the size of the particle being observed, likely results from the
aggregation of multiple nontoxic components. This aggregation explains
the size increase of the nontoxic component observed by light
scattering (Fig. 1B).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Circular dichroism (CD) spectra of the 900-kDa complex
at pH 8 (top), pH 6 (middle), and pH 2 (bottom) (A), the nontoxic
component at pH 2 (top), pH 6 (middle), and pH 8 (bottom) (B), and
botulinum neurotoxin at pH 8 (top), pH 6 (middle), and pH 2 (bottom)
(C).
|
|
The greatest change in secondary structure occurred with the botulinum
neurotoxin. Circular dichroism spectroscopy on botulinum toxin and its
separated components at pH 8.1 have shown that approximately 70% of
the amino acid residues exist in an ordered structure (30). Previous reports of circular dichroic data from pH 9 to 6 revealed a
slight increase in alpha helicity (8). Our results for
botulinum neurotoxin show an increase in helicity on moving from pH 8 to 6 (Fig. 3C). However, a larger increase in helicity occurred on moving from pH 6 to 2. This increase in helicity may be due to a
conformational change in the translocation domain of the neurotoxin, which is known to form pores upon exposure to acidic pH (4). If the neurotoxin increases its helicity at pH 2, producing more secondary structure, then botulinum neurotoxin does not unfold in an
acidic environment. Consequently, the huge increase in hydrodynamic radius indicated by light scattering (Fig. 1A) is most likely caused by
a conformational change in the molecular structure, followed by
oligomerization or aggregation of the botulinum neurotoxin.
ELISA and surface plasmon resonance.
The nontoxic component
appears to prevent the vulnerable regions of the botulinum neurotoxin
from protease attack, acid hydrolysis, and aggregation at low pH.
Epitope mapping suggests that in the 900-kDa complex, the nontoxic
component covers a large portion of the binding domain of botulinum
neurotoxin (5). Previous experiments have shown that the
binding domain is highly susceptible to trypsin cleavage
(28). Therefore, the nontoxic component may play an
important role in protecting the binding domain in the gastrointestinal
tract. Furthermore, ELISA performed on botulinum neurotoxin after
pepsin and intestinal proteolysis showed that antibodies no longer bind
to it, suggesting that cleavage, denaturation, or both have
occurred. In addition to being highly susceptible to proteolysis,
botulinum neurotoxin appears to stick strongly and irreversibly to
lipid monolayers such as POPC, a lipid commonly found in membranes of
cells lining the gastrointestinal tract (9). Using surface
plasmon resonance, we found that botulinum neurotoxin injected over
POPC monolayers adsorbed strongly whereas the 900-kDa complex did not.
Similarly, unless the toxic component was in its complexed form, it
would probably adhere to lipid membranes along the gastrointestinal
tract. Additional evidence for the association of botulinum
neurotoxin with phospholipids has been seen by several
researchers (17, 24, 25, 27). Thus, without the nontoxic
component for protection, botulinum neurotoxin might never leave
the gastrointestinal tract but instead be digested like most other
proteins.
Sugar binding.
The only known ability of the nontoxic
component is its capacity to bind certain sugars (1). Upon
binding these sugars, the nontoxic component is able to agglutinate, or
clump together, cells (19). Whether this property aids the
neurotoxin in reaching its target is under investigation. The clumping
of RBC was monitored with agglutination assays (Table 1). Previous work
has shown that the 14-, 19-, 21-, 35-, and 52-kDa bands are primarily
responsible for agglutination (14, 32). Unproteolyzed
nontoxic component containing these five bands was able to agglutinate
RBC at 37°C (Table 1). After proteolysis by pepsin (pH 2), the
nontoxic component experienced a slight decrease in agglutination
ability (Table 1). Upon exposure to sequential protease incubations,
the nontoxic component showed the largest decrease in the ability to
agglutinate RBC (Table 1). This decrease appears to correlate with the
loss of the 120- and 106-kDa bands (Table 1). The 106-kDa band was shown to be a proteolyzed portion of the 120-kDa band (14). Therefore, the 120-kDa band appears to be necessary for the
nontoxic component to maintain optimal agglutination ability by
protecting the other proteins but is not directly involved in
agglutination. When unproteolyzed or exposed to pepsin, the complex
showed a low ability to agglutinate (Table 1). Upon exposure to a
sequential pepsin and intestinal cocktail incubation, the complex
increased its ability to agglutinate RBC (Table 1). The sequentially
proteolyzed complex contains the 14-, 19-, 21-, 35-, and 52-kDa bands
plus the 100- and 50-kDa bands corresponding to botulinum neurotoxin (Table 1). Thus, the presence of botulinum neurotoxin appears to
protect the ability of the complex to agglutinate after a sequential protease incubation.
These experiments indicate that in order for the nontoxic component to
maintain optimal agglutination activity, it must be part of the 900-kDa
complex while traveling through the gastrointestinal tract. After
exposure to the conditions simulating the gastrointestinal tract, the
900-kDa complex appears to be modified so that the agglutination
ability is activated. We propose that the 900-kDa complex may then
interact with sugars on RBC and release the 150-kDa neurotoxin into the
circulatory system. Although further experiments are necessary,
experiments in which the 900-kDa complex was incubated with RBC that
were subsequently pelleted by centrifugation and washed in saline
solution (0.85% NaCl) showed that the neurotoxin was released and
remained active in the supernatant (21). In addition, the
neurotoxin has been shown to separate from the nontoxic component when
the latter is bound to a sugar affinity column (23) and
eluted with buffers at basic pH and ionic strength.
The 900-kDa complex form of botulinum neurotoxin is necessary for the
delivery of botulinum neurotoxin in its most potent form. Using
purified material and examining the results of the different toxin
species at the molecular level, we have provided further evidence that
the neurotoxin must exist in the 900-kDa complex to maintain its
activity in conditions mimicking the environment of the
gastrointestinal tract. In addition, a synergistic partnership between
botulinum neurotoxin and the nontoxic component in which the nontoxic
portion preserves the toxic ability of the toxic portion and the toxic
portion protects the agglutinating ability of the nontoxic component
seems to exist. In the 900-kDa complex, the neurotoxin and nontoxic
component protect each other from pH extremes and gastrointestinal
proteases. In contrast, when separated and exposed to simulated
digestive conditions, each component is degraded. Although the
molecular mechanism of the neurotoxin's journey to the neuromuscular
junction is still unclear, these biophysical studies provide further
evidence and detail as to the importance of the 900-kDa complex in the
potent oral toxicity of botulinum neurotoxin.
 |
ACKNOWLEDGMENTS |
F. Chen and G. M. Kuziemko contributed equally to the work.
We thank B. R. DasGupta and Bill Tepp for generous supplies of
botulinum neurotoxin, 900-kDa complex, and nontoxic component. We also
thank the lab of Ignacio Tinoco, Jr., especially Barbara Dengler, for
use of their circular dichroism spectropolarimeter.
This work was supported in part by the U.S. Army Medical Research and
Development Command (DAMD17-93-C-3118), an NSF Young Investigator
Award (R.C.S.), U.S. Department of Energy contract DE-AC03-76SF0098, and a National Institutes of Health
predoctoral traineeship from the Neurobiology Division, University of
California, Berkeley.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Chemistry, University of California, Berkeley, CA 94720. Phone: (510) 643-8285. Fax: (510) 643-9290. E-mail:
stevens{at}adrenaline.berkeley.edu.
Editor: J. T. Barbieri
 |
REFERENCES |
| 1.
|
Balding, P.,
E. R. Gold,
D. A. Boroff, and T. A. Roberts.
1973.
Observations on receptor specific proteins. II. Haemagglutination and haemagglutination-inhibition reactions of Clostridial botulinum types A, C, D and E haemagglutinins.
Immunology
25:773-782[Medline].
|
| 2.
|
Beck, W. S.,
K. F. Liem, and A. R. Simpson.
1991.
In
Life, an introduction to biology, 3rd ed., p. 666-676.
Harper Collins Publishers, Inc., New York, N.Y.
|
| 3.
|
Blasl, J.,
E. R. Chapman,
E. Link,
T. Binz,
S. Yamasaki,
P. De Camill,
T. C. Südhof,
H. Niemann, and R. Jahn.
1993.
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.
Nature
365:160-163[Medline].
|
| 4.
|
Blaustein, R. O.,
W. J. Germann,
A. Finkelstein, and B. R. DasGupta.
1987.
The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers.
FEBS Lett.
226:115-120[Medline].
|
| 5.
|
Chen, F.,
G. M. Kuziemko,
P. Amersdorfer,
C. Wong,
J. D. Marks, and R. C. Stevens.
1997.
Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.
Infect. Immun.
65:1626-1630[Abstract].
|
| 6.
|
DasGupta, B. R., and D. A. Boroff.
1968.
Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration.
J. Biol. Chem.
243:1065-1072[Abstract/Free Full Text].
|
| 7.
|
DasGupta, B. R.,
D. A. Boroff, and E. Rothstein.
1966.
Chromatographic fractionation of the crystalline toxin of Clostridium botulinum type A.
Biochem. Biophys. Res. Commun.
22:750-756[Medline].
|
| 8.
|
Datta, A., and B. R. DasGupta.
1988.
Circular dichroic and fluorescence spectroscopic study of the conformation of botulinum neurotoxin types A and E.
Mol. Cell. Biochem.
79:153-159[Medline].
|
| 9.
|
Dudeja, P. K.,
J. M. Harig,
K. Ramaswamay, and T. A. Brasitus.
1989.
Protein-lipid interaction in human small intestinal brush-border membranes.
Am. J. Physiol.
257:G809-G817[Abstract/Free Full Text].
|
| 10.
|
Fling, S. P., and D. S. Gregerson.
1988.
Peptide and protein molecular weight determination by electrophoresis using a high-molarity Tris buffer system without urea.
Anal. Biochem.
155:83-88.
|
| 11.
|
Fujita, R.,
Y. Fujinaga,
K. Inoue,
H. Nakajima,
H. Kumon, and K. Oguma.
1995.
Molecular characterization of two forms of nontoxic-nonhemagglutinin components of Clostridium botulinum type A progenitor toxins.
FEBS Lett.
376:41-44[Medline].
|
| 12.
|
Hayashi, T.,
H. McMahon,
S. Yamasaki,
T. Binz,
Y. Hata,
T. C. Südhof, and H. Niemann.
1994.
Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.
EMBO J.
2:5051-5061.
|
| 13.
|
Heckly, R. J.,
G. J. Hildebrand, and C. Lamanna.
1960.
On the size of the toxic particle passing the intestinal barrier in botulism.
J. Exp. Med.
111:745-759[Abstract].
|
| 14.
|
Inoue, K.,
Y. Fujinaga,
T. Watanabe,
T. Ohyama,
K. Takeshi,
K. Moriishi,
H. Nakajima,
K. Inoue, and K. Oguma.
1996.
Molecular composition of Clostridium botulinum type A progenitor toxins.
Infect. Immun.
64:1589-1594[Abstract].
|
| 15.
|
Johnson, L. R.
1981.
In
Physiology of the gastrointestinal tract, p. 625-627.
Raven Press Books, Ltd., New York, N.Y.
|
| 16.
|
Johnson, L. R.
1981.
In
Physiology of the gastrointestinal tract, p. 784-787.
Raven Press Books, Ltd., New York, N.Y.
|
| 17.
|
Kamata, Y.,
Y. Kimura, and S. Kozaki.
1994.
Involvement of phospholipids in the intoxication mechanism of botulinum neurotoxin.
Biochim. Biophys. Acta
1199:65-68[Medline].
|
| 18.
|
Kozaki, S.,
A. Miki,
Y. Kamata,
T. Nagai,
J. Ogasawara, and G. Sakaguchi.
1989.
Immunological characterization of the papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes.
Infect. Immun.
57:2634-2639[Abstract/Free Full Text].
|
| 19.
|
Lamanna, C.
1948.
Hemagglutination by botulinal toxin.
Proc. Soc. Exp. Biol. Med.
69:332-336[Medline].
|
| 20.
|
Lowenthal, J. P., and C. Lamanna.
1951.
Factors affecting the botulinal hemagglutination reaction, and the relationship between hemagglutinating activity and toxicity of toxin preparations.
Am. J. Hyg.
54:342-353.
|
| 21.
|
Lowenthal, J. P., and C. Lamanna.
1953.
Characterization of botulinal hemagglutination.
Am. J. Hyg.
57:46-59.
|
| 22.
|
May, A. J., and B. C. Whaler.
1958.
The absorption of Clostridium botulinum type A toxin from the alimentary canal.
Br. J. Exp. Pathol.
39:307-316[Medline].
|
| 23.
|
Moberg, L. J., and H. Sugiyama.
1978.
Affinity chromatography purification of type A botulinum neurotoxin from crystalline toxin complex.
Appl. Environ. Microbiol.
35:878-880[Abstract/Free Full Text].
|
| 24.
|
Montecucco, C.,
G. Schiavo,
Z. Gao,
E. Bauerlein,
P. Boquet, and B. R. DasGupta.
1988.
Interaction of botulinum and tetanus toxins with the lipid bilayer surface.
Biochem. J.
251:379-383[Medline].
|
| 25.
|
Montecucco, C.,
G. Schiavo, and B. R. DasGupta.
1989.
Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes.
Biochem. J.
259:47-53[Medline].
|
| 26.
|
Ohishi, I.,
S. Sugii, and G. Sakaguchi.
1977.
Oral toxicities of Clostridium botulinum in response to molecular size.
Infect. Immun.
16:107-109[Abstract/Free Full Text].
|
| 27.
|
Schmid, M. F.,
J. P. Robinson, and B. R. DasGupta.
1993.
Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles.
Nature
364:827-830[Medline].
|
| 28.
|
Shone, C. C.,
P. Hambleton, and J. Melling.
1985.
Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments.
Eur. J. Biochem.
151:75-82[Medline].
|
| 29.
|
Simpson, L. L.
1980.
Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.
J. Pharmacol. Exp. Ther.
212:16-21[Abstract/Free Full Text].
|
| 30.
|
Singh, B. R., and B. R. DasGupta.
1989.
Structure of heavy and light chain subunits of type A botulinum neurotoxin analyzed by circular dichroism and fluorescence measurements.
Mol. Cell. Biochem.
85:67-73[Medline].
|
| 31.
|
Singh, B. R.,
B. Li, and D. Read.
1995.
Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison?
Toxicon
33:1541-1547[Medline].
|
| 32.
|
Somers, E., and B. R. DasGupta.
1991.
Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes?
J. Protein Chem.
10:415-425[Medline].
|
| 33.
|
Sugii, S.,
I. Ohishi, and G. Sakaguchi.
1977.
Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes.
Infect. Immun.
16:910-914[Abstract/Free Full Text].
|
| 34.
|
Sugii, S.,
I. Ohishi, and G. Sakaguchi.
1977.
Intestinal absorption of botulinum toxins of different molecular sizes in rats.
Infect. Immun.
17:491-496[Abstract/Free Full Text].
|
| 35.
|
Sugiyama, H.
1980.
Clostridium botulinum neurotoxin.
Microbiol. Rev.
44:419-448[Free Full Text].
|
| 36.
|
Tacket, C. O., and M. A. Rogawski.
1989.
Botulism, p. 354-356.
In
L. L. Simpson (ed.), Botulinum neurotoxin and tetanus toxin. Academic Press, Inc., San Diego, Calif.
|
| 37.
|
Wagman, J., and J. B. Bateman.
1953.
Botulinum type A toxin: properties of a toxic dissociation product.
Arch. Biochem. Biophys.
45:375-383[Medline].
|
Infect Immun, June 1998, p. 2420-2425, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Couesnon, A., Raffestin, S., Popoff, M. R.
(2006). Expression of botulinum neurotoxins A and E, and associated non-toxin genes, during the transition phase and stability at high temperature: analysis by quantitative reverse transcription-PCR.. Microbiology
152: 759-770
[Abstract]
[Full Text]
-
Sharma, S. K., Ferreira, Joseph. L., Eblen, B. S., Whiting, R. C.
(2006). Detection of Type A, B, E, and F Clostridium botulinum Neurotoxins in Foods by Using an Amplified Enzyme-Linked Immunosorbent Assay with Digoxigenin-Labeled Antibodies. Appl. Environ. Microbiol.
72: 1231-1238
[Abstract]
[Full Text]
-
Franciosa, G., Floridi, F., Maugliani, A., Aureli, P.
(2004). Differentiation of the Gene Clusters Encoding Botulinum Neurotoxin Type A Complexes in Clostridium botulinum Type A, Ab, and A(B) Strains. Appl. Environ. Microbiol.
70: 7192-7199
[Abstract]
[Full Text]
-
Voth, D. E., Qa'Dan, M., Hamm, E. E., Pelfrey, J. M., Ballard, J. D.
(2004). Clostridium sordellii Lethal Toxin Is Maintained in a Multimeric Protein Complex. Infect. Immun.
72: 3366-3372
[Abstract]
[Full Text]
-
Park, J.-B., Simpson, L. L.
(2003). Inhalational Poisoning by Botulinum Toxin and Inhalation Vaccination with Its Heavy-Chain Component. Infect. Immun.
71: 1147-1154
[Abstract]
[Full Text]
-
Schiavo, G., Matteoli, M., Montecucco, C.
(2000). Neurotoxins Affecting Neuroexocytosis. Physiol. Rev.
80: 717-766
[Abstract]
[Full Text]
-
Maksymowych, A. B., Reinhard, M., Malizio, C. J., Goodnough, M. C., Johnson, E. A., Simpson, L. L.
(1999). Pure Botulinum Neurotoxin Is Absorbed from the Stomach and Small Intestine and Produces Peripheral Neuromuscular Blockade. Infect. Immun.
67: 4708-4712
[Abstract]
[Full Text]